In an effort to control healthcare costs, provide healthcare to the uninsured and underinsured, and improve health outcomes, there has been growing interest among politicians and the public
Amgen has chalked up a victory in a patent infringement lawsuit with Regeneron over blockbuster ophthalmic drug Eylea and decided to launch its biosimilar in the US – even though the legal